查詢結果分析
來源資料
相關文獻
- 慢性骨髓性白血病藥物治療的進展
- 慢性骨髓性白血病治療之最新進展
- 慢性骨髓性白血病之進步--治療及疾病監測
- 慢性骨髓性白血病
- Complete Recovery from Dasatinib-Induced Pulmonary Arterial Hypertension after Successful Discontinuation of Tyrosine Kinase Inhibitor in a Case of Chronic Myeloid Leukemia
- 慢性骨髓性白血病的新治療
- 尼羅替尼相關顎骨壞死--罕見病例報告
- Treatment of Chronic Myelocytic Leukemia by Allogeneic Bone Marrow Transplantation in Eleven Patients
- 慢性骨髓性白血病以Legg-Calve'-Perthes症出現--談全身體檢的重要
- STI 571(Signal Transduction Inhibitor 571):治療慢性骨髓性白血病的新里程碑
頁籤選單縮合
題名 | 慢性骨髓性白血病藥物治療的進展=The New Evolution of Therapeutic Drug for Chronic Myeloid Leukemia |
---|---|
作者 | 吳雅惠; 李建瑩; Wu, Ya-hui; Lee, Chien-ying; |
期刊 | 藥學雜誌 |
出版日期 | 20160900 |
卷期 | 32:3=128 2016.09[民105.09] |
頁次 | 頁74-80 |
分類號 | 415.635 |
語文 | chi |
關鍵詞 | 慢性骨髓性白血病; BCR-ABL融合基因; 酪胺酸激酶抑制劑; Chronic myeloid leukemia; BCR-ABL fusion gene; Tyrosine kinase inhibitor; |
中文摘要 | 許多慢性骨髓性白血病人者會攜帶費城染色體基因異常,是由於第9對染色體和 第22對染色體之間的相互易位產生,帶有 BCR-ABL (breakpoint cluster region-abelson) 融合基因編碼組成活性的酪氨酸激酶蛋白質,引起骨髓系細胞大量增殖及分裂。 酪胺酸激酶抑制劑為治療慢性骨髓性白血病的首選治療藥物,顯著提高長期存活 率及快速達到分子學反應。Imatinib 是最早用來治療慢性骨髓性白血病的酪胺酸激酶 抑制劑,但有些病人會對其產生抗藥性及耐受不良,於是第二代酪胺酸激酶抑制劑成 為使用第一線 imatinib 藥物治療慢性骨髓性白血病人者失敗時的另一項選擇,能達到 較佳治療效果。 |
英文摘要 | Most patients with chronic myeloid leukemia carry a genetic abnormality referred to known as the Philadelphia chromosome, resulting of a reciprocal translocation between chromosomes 9 and 22, fusion gene that encodes a constitutively active BCR-ABL tyrosine kinase protein. This situation causes the excess proliferation and split of myeloid cells. Tyrosine kinase inhibitors(TKIs) are the initial treatment for patients with chronic myeloid leukemia (CML), it could significantly increase long-term survival and achieve molecular responses rapidly. Imatinib was the agent approved for the treatment of chronic myeloid leukemia. Some patients may acquire resistance or intolerance to imatinib. The timing of second-line TKIs treatment after failure of initial treatment may have a significant impact on long-term outcome. Thus, second generation TKIs is an another choice and may attainment of better results. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。